TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Condition:   B7-H3-positive Relapsed/ Refractory Neuroblastoma Intervention:   Biological: T cell injection targeting FLT3 chimeric antigen receptor Sponsor:   PersonGen BioTherapeutics (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials